Do Concurrent Multiple Infections with High-Risk HPVs Carry a More Malignant Potential Than a Single Infection in the Uterine Cervix?

Overview

Journal J Clin Med

Specialty General Medicine

Date 2023 Oct 14

PMID 37834799

Authors

Juhun Lee

Hyun Jung Lee

Affiliations

Soon will be listed here.

Abstract

The high-risk human papillomavirus (HR-HPV) has been known as the most important carcinogen in uterine cervical carcinoma. However, there is limited evidence of the malignant potential of these concurrent multiple infections. This study included women who had undergone cervical conization. They underwent an HPV test by cervical swab within 12 months before the surgery. They were divided into two groups: one with a single infection with HR-HPV16 and the other with concurrent multiple infections with HR-HPVs, including genotype 16. Pathologic examination classified cases as CIS+ to assess and compare the malignant potential in both groups, including carcinoma in situ (CIS) and invasive carcinoma. Of the 220 patients infected with HR-HPV16, the single infection group consisted of 120 patients (54.5%), whereas the concurrent multiple infections consisted of 100 (45.5%) patients. The rates of HSIL were significantly higher in the concurrent multiple infection group. However, the odds ratio for CIS+ did not show a significant difference between both groups (1.417, 95% CI = 0.831-2.414, = 0.200). The malignant potential was not significantly different between concurrent multiple infections with HR-HPVs, including 16, and a single infection with 16 in Korean women.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Gupta S, Kumar P, Das B . HPV: Molecular pathways and targets. Curr Probl Cancer. 2018; 42(2):161-174. DOI: 10.1016/j.currproblcancer.2018.03.003. View

Ko K, Kwon M, Lee E, Woo H, Park H . Comparison of GeneFinder human papillomavirus (HPV) Liquid Beads Microarray PCR Kit and Hybrid Capture 2 Assay for Detection of HPV Infection. J Clin Lab Anal. 2016; 31(2). PMC: 6816898. DOI: 10.1002/jcla.22025. View

de Sanjose S, Quint W, Alemany L, Geraets D, Klaustermeier J, Lloveras B . Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11(11):1048-56. DOI: 10.1016/S1470-2045(10)70230-8. View

Munoz N, Bosch F, de Sanjose S, Herrero R, Castellsague X, Shah K . Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348(6):518-27. DOI: 10.1056/NEJMoa021641. View

Clifford G, Gallus S, Herrero R, Munoz N, Snijders P, Vaccarella S . Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005; 366(9490):991-8. DOI: 10.1016/S0140-6736(05)67069-9. View

Lehtinen M, Dillner J . Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol. 2013; 10(7):400-10. DOI: 10.1038/nrclinonc.2013.84. View

Zur Hausen H . Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002; 2(5):342-50. DOI: 10.1038/nrc798. View

Mantovani F, Banks L . The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene. 2001; 20(54):7874-87. DOI: 10.1038/sj.onc.1204869. View

10.

Wheeler C, Hunt W, Cuzick J, Langsfeld E, Pearse A, Montoya G . A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination. Int J Cancer. 2012; 132(1):198-207. PMC: 3852415. DOI: 10.1002/ijc.27608. View

11.

de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N . Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007; 7(7):453-9. DOI: 10.1016/S1473-3099(07)70158-5. View

12.

Vaccarella S, Franceschi S, Snijders P, Herrero R, Meijer C, Plummer M . Concurrent infection with multiple human papillomavirus types: pooled analysis of the IARC HPV Prevalence Surveys. Cancer Epidemiol Biomarkers Prev. 2010; 19(2):503-10. DOI: 10.1158/1055-9965.EPI-09-0983. View

13.

Maucort-Boulch D, Franceschi S, Plummer M . International correlation between human papillomavirus prevalence and cervical cancer incidence. Cancer Epidemiol Biomarkers Prev. 2008; 17(3):717-20. DOI: 10.1158/1055-9965.EPI-07-2691. View

14.

An H, Song K, Balasaheb Nimse S, Kim J, Nguyen V, Ta V . HPV 9G DNA chip: 100% clinical sensitivity and specificity. J Clin Microbiol. 2011; 50(3):562-8. PMC: 3295105. DOI: 10.1128/JCM.06217-11. View

15.

Bosch F, de Sanjose S . Chapter 1: Human papillomavirus and cervical cancer--burden and assessment of causality. J Natl Cancer Inst Monogr. 2003; (31):3-13. DOI: 10.1093/oxfordjournals.jncimonographs.a003479. View

16.

Gonzalez S, Stremlau M, He X, Basile J, Munger K . Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7. J Virol. 2001; 75(16):7583-91. PMC: 114993. DOI: 10.1128/JVI.75.16.7583-7591.2001. View

17.

Oh C, Won Y, Jung K, Kong H, Cho H, Lee J . Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2013. Cancer Res Treat. 2016; 48(2):436-50. PMC: 4843732. DOI: 10.4143/crt.2016.089. View

18.

Park E, Kim J, Choi S, Kim D, Oh Y . Carcinogenic risk of human papillomavirus (HPV) genotypes and potential effects of HPV vaccines in Korea. Sci Rep. 2019; 9(1):12556. PMC: 6715722. DOI: 10.1038/s41598-019-49060-w. View

19.

Tjalma W, Fiander A, Reich O, Powell N, Nowakowski A, Kirschner B . Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int J Cancer. 2012; 132(4):854-67. DOI: 10.1002/ijc.27713. View

20.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View